Has anyone mentioned AltaRex (AEX.ASE) @ $1.83.
Dr. A. Noujaim, President and CEO of AltaRex was President and CEO of BIOMIRA (also once under $2.00 before hitting $30).
Email me for more info if interested.
Thoughts?
Sam. (sorry for size of post but this is just a summary)
----------------------------------------------------------------------
"AltaRex focuses on the development and discovery of products for the
treatment and diagnosis of Cancer. These products are based on AltaRex's platform technology which is known as Anti-idiotype Induction Therapy (``AIT(TM)''). AIT(TM) is based on the ability of the human immune system to respond, when stimulated, to the presence of a tumour. AltaRex also has products for the treatment of breast and colorectal cancer in pre-clinical development."
----------------------------------------------------------------------
This is a cancer research company that has developed an Ovarian Cancer Vaccine (OVAREX) and currently has just recieved approval for phase II/III trials in Canada and Europe.
They have also hooked up with Medac of Hamburg, Germany and have been granted North American marketing rights for Treosulfan (OVASTAT).
Wed 6 Nov 96
"Treosulfan is an alkylating agent having a therapeutic index comparable to or higher than cyclophosphamide. The incidence of toxic effects, on other organs (liver, kidneys, heart, lungs) as well as hair loss are low, making it a suitable candidate for inclusion in high dose chemotherapy regimens. In addition to being effective in the treatment of ovarian cancer, pre-clinical evaluations show that Treosulfan has impressive antitumor activity against various breast, lung, and renal cell carcinomas. Treosulfan was shown to be comparable to or more effective than many commonly used cytostatic agents. Lack of cross-resistance between treosulfan and other chemotherapeutic agents such as doxorubicin and cisplatin has been demonstrated in vitro with ovarian, breast, and renal cell carcinoma cell lines."
---------------------------------------------------------------------
October 23, 1996
They also recently signed a "research collaboration agreement with the University of Alberta for the commercialization of the Hypocrellin technology. Hypocrellin, a substance originally extracted from the Chinese mushroom,has been totally synthesized by a University team led
by world-renowned Professor W. Lown of the Chemistry Department of the
University of Alberta. Hypocrellin is a substance that destroys tumors when activated with a laser light. When combined with AltaRex's targeting antibodies technology it will provide a new class of powerful agents for the immunophotodynamic therapy of cancer. The first application of this technology will be in the field of ovarian cancer to assist the surgeons in the removal of small masses of disease as well as immunizing the patients through AltaRex's AIT(TM) OVAREX(TM) vaccine. This unique combination of photoactivation and immune stimulation activities has already been tested in a limited number of patients by AltaRex and found to produce very satisfactory
results." |
